drugset / Trial / NCT03315000

Effect of Vilanterol on Methacholine Challenge Results

NCT03315000

Phase 4 Completed 17 enrolled University of Saskatchewan
RandomizedCrossoverTriple-blindTreatment

Summary

The study will assess the degree of bronchoprotection provided by the ultra long-acting beta2 agonist vilanterol against methacholine-induced bronchoconstriction.

Timeline

Start
2017-10-13
Primary completion
2018-05-01
Completion
2018-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 100 ug Inhaled
Subject Vilanterol Other / unclassified 25 ug Inhaled

Indications